Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics tags : Phase 2b save search
NeuroSense Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study
Published: 2023-02-06 (Crawled : 14:20) - neurosense.investorroom.com
NRSN | News | $1.33 -2.21% -2.26% 130K
|
|
| O: -4.91%
H: 5.81%
C: 1.94%
fda canada als trial potential study phase 2b
Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023
Published: 2023-02-03 (Crawled : 12:20) - globenewswire.com
CLDX | $36.975 -2.11% -2.15% 390K
|
Health Technology
|
| O: -1.2%
H: 4.11%
C: 3.71%
immunology meeting urticaria therapeutics presentation results phase 2b
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
Published: 2023-01-30 (Crawled : 13:20) - biospace.com/
VERA | $39.94 1.06% 1.05% 770K
|
Professional, Scientific, and T...
|
| O: -15.1%
H: 15.5%
C: 10.65%
treatment nephropathy week trial therapeutics phase 2b
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
Published: 2023-01-22 (Crawled : 20:20) - globenewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: 55.66%
H: 4.17%
C: -13.58%
fibrosis trial therapeutics positive phase 2b
Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
Published: 2023-01-18 (Crawled : 12:20) - globenewswire.com
MNPR | $0.63 -3.08% -3.17% 39K
|
Health Technology
|
| O: 16.49%
H: 0.0%
C: -12.31%
trial phase 2b
Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma
Published: 2023-01-18 (Crawled : 12:20) - globenewswire.com
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 3.23%
H: 0.0%
C: -6.25%
treatment trial therapeutics plus phase 2b glioblastoma
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease
Published: 2023-01-09 (Crawled : 14:00) - biospace.com/
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: 4.84%
H: 11.79%
C: -6.67%
trappsol treatment disease therapeutics alzheimer’s study phase 2b
Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Published: 2023-01-09 (Crawled : 12:20) - prnewswire.com
VKTX | $65.03 0.15% 0.15% 2.6M
|
Health Technology
|
| O: 0.12%
H: 3.85%
C: -0.36%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: 0.64%
H: 0.55%
C: -0.13%
vk2809 therapeutics study phase 2b
Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress
Published: 2023-01-05 (Crawled : 13:00) - biospace.com/
MCRB | $0.7295 -4.01% -4.18% 5.8M
|
Health Technology
|
| O: 0.37%
H: 0.0%
C: -2.55%
ser-155 genomic therapeutics study phase 2b
Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
CMMB | $0.67 0.02% 3.4K
|
Manufacturing
|
| O: 50.31%
H: 11.23%
C: -38.88%
cm-101 fibrosis liver biomarker trial results nash phase 2b
Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer
Published: 2022-12-21 (Crawled : 23:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 2.98%
H: 2.99%
C: 2.14%
fda designation therapy cancer phase 2b
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
Published: 2022-12-21 (Crawled : 21:00) - ir.akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -0.02%
H: 6.34%
C: 6.12%
expected therapeutics study phase 2b
Cerevel Therapeutics Announces Publication in The Lancet of Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia
Published: 2022-12-15 (Crawled : 00:00) - globenewswire.com
CERE | $41.87 -0.29% -0.29% 630K
|
Finance
|
| O: -1.59%
H: 2.35%
C: 0.96%
schizophrenia trial therapeutics living publication phase 2b
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
Published: 2022-12-15 (Crawled : 21:00) - biospace.com/
TARS | $32.77 -2.79% -2.87% 320K
|
Health Technology
|
| O: -2.13%
H: 1.3%
C: 0.68%
tp-05 disease topline trial positive phase 2b
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss
Published: 2022-12-15 (Crawled : 13:20) - biospace.com/
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -2.18%
H: 0.0%
C: -0.83%
fx-345 candidate therapeutics study phase 2b
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)
Published: 2022-12-12 (Crawled : 13:00) - biospace.com/
APVO | $0.6827 -7.27% -7.84% 570K
|
Health Technology
|
| O: 98.09%
H: 4.65%
C: -43.17%
apvo436 treatment leukemia trial acute myeloid leukemia aml phase 2b
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASHDesignation based on Akero’s Phase 2b HARMONY study
Published: 2022-12-08 (Crawled : 00:00) - biospace.com/
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.93%
H: 5.17%
C: 2.47%
fda designation granted therapy study efruxifermin phase 2b
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
Published: 2022-12-06 (Crawled : 15:20) - biospace.com/
CLDX | $36.975 -2.11% -2.15% 390K
|
Health Technology
|
| O: -0.33%
H: 3.35%
C: -0.55%
global urticaria therapeutics positive study phase 2b
Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
Published: 2022-12-05 (Crawled : 19:00) - biospace.com/
DNLI | $15.55 -3.48% -3.6% 940K
|
Health Technology
|
| O: 1.01%
H: 0.09%
C: -6.13%
dnl343 als trial therapeutics platform phase 2b
Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)
Published: 2022-12-01 (Crawled : 14:20) - biospace.com/
CMPX | $1.49 -1.97% -2.01% 150K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 14.36%
C: 11.92%
ctx-471 keytruda trial therapeutics phase 2b
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.